Related Experiment Video
Updated: Jul 5, 2026
Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Lipoxygenase pathway receptor expression in ovarian cancer
Rodney P Rocconi1, Tyler O Kirby, Robert S Seitz
1Department of Obstetrics and Gynecology, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama 36607, USA. rocconi@usouthal.edu
Objective:
To determine the expression of lipoxygenase (LOX) pathway receptors in ovarian cancer as a potential target for anti-LOX-based therapy.
Study Design:
Paraffin-embedded tumor samples from epithelial ovarian cancer patients were used to construct tissue microarrays to stain for the proposed sites of inhibition of a LOX inhibitor (5-LOX, LTB4-BLT1, and LTB4-BLT2).
Results:
245 samples were available for interpretation. Strong expression was demonstrated in 45%, 34%, and 6% of ovarian cancer for LTB4-BLT2, LTB4-BLT1, and 5-LOX, respectively. Expression of LTB4-BLT2 correlated with advanced stage III/IV disease (P = .05), suboptimal debulking (P = .07), and platinum resistance (P = .03). No correlation was seen with regard to disease-free survival.
Conclusions:
LOX pathway receptor expression was found in the majority of cancers evaluated. Additionally, LTB4-BLT2 expression portends worse clinical parameters for ovarian cancer. Thus, further investigation on the role of LOX pathway in ovarian cancer is warranted.
Insights
Lipoxygenase (LOX) pathway receptors are present in most ovarian cancers. LTB4-BLT2 expression is linked to advanced disease and platinum resistance, suggesting LOX as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The lipoxygenase (LOX) pathway plays a role in inflammation and cancer progression.
- Identifying novel therapeutic targets in ovarian cancer is crucial for improving patient outcomes.
Purpose of the Study:
- To investigate the expression of lipoxygenase (LOX) pathway receptors in epithelial ovarian cancer.
- To evaluate the potential of these receptors as targets for anti-LOX-based therapies.
Main Methods:
- Tissue microarrays were constructed from paraffin-embedded ovarian cancer samples.
- Immunohistochemical staining was performed to detect the expression of 5-LOX, LTB4-BLT1, and LTB4-BLT2.
Main Results:
- Lipoxygenase (LOX) pathway receptors were detected in a significant proportion of ovarian cancers.
- LTB4-BLT2 expression was observed in 45% of samples and correlated with advanced stage (III/IV), suboptimal debulking, and platinum resistance.
- LTB4-BLT1 and 5-LOX expression were found in 34% and 6% of samples, respectively, with no correlation to disease-free survival.
Conclusions:
- Lipoxygenase (LOX) pathway receptors are expressed in the majority of ovarian cancers evaluated.
- LTB4-BLT2 expression is associated with poorer clinical parameters in ovarian cancer, indicating its potential as a therapeutic target.
- Further research into the role of the LOX pathway in ovarian cancer is warranted.
